MarkTRedingMD
Oncology • Minneapolis, MNAssistant Professor, Medicine, University of Minnesota Medical School
Are you Dr. Reding?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 50 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
420 Delaware St Se
Mmc 480
Minneapolis, MN 55455Phone+1 612-625-1104
Summary
- Dr. Mark Reding, MD is an oncologist in Minneapolis, Minnesota. He is currently licensed to practice medicine in Minnesota. He is affiliated with M Health Fairview University of Minnesota Medical Center, M Health Fairview Southdale Hospital, and M Health Fairview Ridges Hospital.
Education & Training
University of MinnesotaFellowship, Hematology and Medical Oncology, 1996 - 1999- University of MinnesotaResidency, Internal Medicine, 1992 - 1995
- University of Minnesota Medical SchoolClass of 1992
Certifications & Licensure
MN State Medical License 1994 - 2025
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Inhibitor Development in Patients With Hemophilia A Undergoing Surgery Start of enrollment: 2011 Nov 01
- Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B Start of enrollment: 2013 Feb 11
- Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis Start of enrollment: 2014 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 52 citationsAnti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support.Sirtaz Adatya, Nir Uriel, Hirad Yarmohammadi, Christopher T. Holley, Amy Feng
JACC. Heart Failure. 2015-04-01 - 69 citationsHemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survivalL. E. Lunde, S. Dasaraju, Qing Cao, Claudia S. Cohn, Mark T. Reding
Bone Marrow Transplantation. 2015-11-01 - 44 citationsTwo-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.Johnny Mahlangu, Radoslaw Kaczmarek, Annette von Drygalski, Susan Shapiro, Sheng-Chieh Chou
The New England Journal of Medicine. 2023-02-23
Press Mentions
Bayer to Present Results from Head-to-Head PK Comparison Study of Jivi® Versus Adynovate® in Late-Breaker Presentation at the Annual World Federation of Hemophilia Virtual SummitJune 15th, 2020
FDA Approves JiviAugust 31st, 2018
